Trial Profile

Medical research council working parties on leukaemia in adults and children. Acute myeloid leukaemia trial 15.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemtuzumab ozogamicin (Primary) ; Amsacrine; Antineoplastics; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Fludarabine; Idarubicin; Lestaurtinib; Mercaptopurine; Mitoxantrone; Tretinoin
Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia
Focus Adverse reactions; Therapeutic Use
Acronyms MRC AML 15

Most Recent Events

12 Aug 2013 Results published in the Journal of Clinical Oncology.
13 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
08 Dec 2009 Results have been reported at the 51st Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com